公開日期 | 標題 | 作者 | 來源出版物 | scopus | WOS | 全文 |
---|---|---|---|---|---|---|
2022 | Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma | ANN-LII CHENG ; Qin, Shukui; Ikeda, Masafumi; Galle, Peter R; Ducreux, Michel; Kim, Tae-You; Lim, Ho Yeong; Kudo, Masatoshi; Breder, Valeriy; Merle, Philippe; Kaseb, Ahmed O; Li, Daneng; Verret, Wendy; Ma, Ning; Nicholas, Alan; Wang, Yifan; Li, Lindong; Zhu, Andrew X; Finn, Richard S | Journal of hepatology | 490 | 463 |